SAN DIEGO– Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio’s DNA and RNA business. This acquisition combines Officinae Bio’s AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies’ leading drug substance manufacturing capabilities, providing customers comprehensive expertise and novel technologies for quick, calculated progression through the mRNA sequence-optimization phase and into clinical testing and commercial manufacturing.
Venice, Italy-based Officinae Bio’s proprietary digital platform accelerates the prototyping of mRNA drug candidates, enabling the rapid testing of diverse combinations of capping analogs, chemical modifications, and sequence designs to advance client discovery programs into the clinic.
“We are thrilled to bring Officinae into the Maravai family, where their talented team will add cutting-edge AI-driven sequence design and seamless e-commerce to our TriLink Discovery business. Together, we intend to accelerate the field of next-generation medicines in mRNA and CRISPR, using best-in-class chemistries, processes, and proprietary technologies like CleanCap® analogs,” said Trey Martin, CEO of Maravai LifeSciences. “This acquisition also marks our first move into the very important European marketplace with a manufacturing footprint. This market access will fuel our growth across multiple product lines in the post-pandemic era.”
Davide De Lucrezia, Chief Executive Officer and co-founder of Officinae Bio commented, “Joining forces with Maravai and TriLink allows us to extend our expertise in AI-driven tools for more customers to accelerate their development and to identify candidate sequences with fewer errors. Along with TriLink’s decades of chemical and biological manufacturing experience, we can now supercharge the design-build-test-learn cycle for our customers.”
Davide will continue to lead the Officinae Bio team, now a business within Maravai’s Nucleic Acid Production segment.
